{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:43:04Z","timestamp":1791229384274,"version":"4.1.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Myeloid neoplasms with platelet-derived growth factor receptor \u03b2 (PDGFRB) rearrangement usually present with eosinophilia in the peripheral blood and bone marrow. Here we report a case of systemic mastocytosis related myeloid neoplasms with basophilia and PRKG2\u2013PDGFRB fusion gene.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient's concerns:<\/jats:title>\n            <jats:p>A 53-year-old male patient felt fatigue with thrombocythemia and normal hemoglobin over 2\u200ayears. Considering the possibility of primary thrombocytosis, the patient was treated with hydroxyurea and interferon. Then the therapy was stopped due to adverse events and worsen condition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Acute myelogenous leukemia (AML) diagnosis was confirmed by bone marrow morphology and flow cytometry. PDGFRB rearrangement was detected by fluorescence in situ hybridization (FISH) test, with chromosome karyotype 46,XY,t(4:5)(q21:q33). PRKG2\u2013PDGFRB fusion was observed by next generation sequencing (NGS) and verified by RT-PCR followed by Sanger sequencing. The results of bone marrow aspiration, bone marrow biopsy, and immunophenotyping showed systemic mastocytosis-related myeloid tumor with basophilia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Imatinib 400\u200amg\/d was given on the day of admission. Azacitidine 75\u200amg\/m<jats:sup>2<\/jats:sup> was given for induction therapy for 10\u200adays, and followed by one course of DHAG consolidating therapy. Imatinib was taken orally continuously.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>On the 8th day of treatment, the patient's diet and fatigue improved. The hematological and bone marrow morphological remission was achieved on the 25th day. Cytogenetic complete remission was achieved 3\u200amonths later and continued to present (December 20, 2020). PRKG2\u2013PDGFRB fusion gene turned negative 7\u200amonths later from diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Patients with increased basophilic granulocyte and\/or mast cells in peripheral blood and\/or bone marrow should be screened for PDGFRB abnormality and myeloid or lymphatic tumor. Patients bearing PDGFRB abnormality have a good response to imatinib.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024707","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T01:03:57Z","timestamp":1614906237000},"page":"e24707","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Myeloid tumors accompanying systemic mastocytosis, basophilia, and abnormal platelet-derived growth factor receptor \u03b2"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-591X","authenticated-orcid":false,"given":"Yanfen","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hematology, Chinese PLA General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese PLA General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wan","sequence":"additional","affiliation":[{"name":"Beijing USCI Medical Laboratory, Beijing, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daihong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese PLA General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.humpath.2017.03.014","article-title":"Acute mast cell leukemia associated with t(4;5)(q21;q33)","volume":"67","author":"Wang","year":"2017","journal-title":"Hum Pathol"},{"key":"R3-20250504","first-page":"4158567","article-title":"A 26-year-old female with systemic mastocytosis with associated myeloid neoplasm with eosinophilia and abnormalities of PDGFRB, t(4;5)(q21;q33)","volume":"2016","author":"Brown","year":"2016","journal-title":"Case Rep Hematol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.10980","article-title":"Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor \u03b2 gene","volume":"92","author":"Walz","year":"2007","journal-title":"Haematologica"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3324\/haematol.11836","article-title":"Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion","volume":"93","author":"Lahortiga","year":"2008","journal-title":"Haematologica"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cancergencyto.2007.10.021","article-title":"Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders","volume":"181","author":"Gallagher","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.20833","article-title":"Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation","volume":"82","author":"Dalal","year":"2007","journal-title":"Am J Hematol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.25371","article-title":"Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management","volume":"94","author":"Pardanani","year":"2019","journal-title":"Am J Hematol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","article-title":"Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models","volume":"2","author":"Pardanani","year":"2018","journal-title":"Blood Adv"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.3324\/haematol.2017.187302","article-title":"Molecular genetic characterization of myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2","volume":"103","author":"Baer","year":"2018","journal-title":"Haematologica"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0009-8981(02)00419-9","article-title":"Antibodies to centromere antigens measured by an automated enzyme immunoassay","volume":"328","author":"Gonz\u00e1lez-Buitrago","year":"2003","journal-title":"Clin Chim Acta"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:10:01Z","timestamp":1746339001000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024707"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":13,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024707","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"2020-11-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}